ACERCA DE ESTE EPISODIO
Prof van Dongen speaks with ecancertv at IBCD 2016 about gaining deeper insight into drug action and suitability with radiolabelling.
He describes how the journey of radiolabelled ligands may steer drug development, aiming for biomarkers and accumulating in tumours with localised tissue damage and low toxicity.
Prof van Dongen describes himself as a tyrosine kinase inhibitor skeptic, calling for greater clarity in patient subtypes.
He describes how the journey of radiolabelled ligands may steer drug development, aiming for biomarkers and accumulating in tumours with localised tissue damage and low toxicity.
Prof van Dongen describes himself as a tyrosine kinase inhibitor skeptic, calling for greater clarity in patient subtypes.
Inglés
Estados Unidos
TRANSCRIPCIÓN 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
BUSCAR EPISODIOS ANTERIORES
Buscar episodios anteriores de IBCD 2016.
OTROS EPISODIOS EN ESTE PODCAST
Dr Golfinopoulos meets with ecancertv at IBCD 2016 to discuss SPECTA: a screening platform that sought to encourage patients to participate in clinical trials.
He describes how regulatory involvement in trial design and drug design could be streamlined, and the issue of reimbursement for personali…
Dr Gerstung speaks with ecancertv at IBCD 2016 about genetic analysis of AML patients that has contributed to a predictive model for treatment risk and outcomes.
He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk of…
Dr Schneider speaks with ecancertv at IBCD 2016 about the regulatory checkpoints to be passed in the development of assays.
He highlights the difference in reproducibility and robustness of research and clinical assays, the clinical utility of validated biomarkers, and how beginning assay developm…
Dr Beer speaks with ecancertv at IBCD 2016 about making use of genomic data in a clinically actionable setting.
He opens with comments on the work of Dr Moritz Gerstung and considers the issues of storage, access and regulation in genomic libraries.
Dr Beer describes how unregulated access and of…
Dr Malik speaks with ecancertv at IBCD 2016 to discuss the work of the National Cancer Institute in recruiting patients to clinical trials when subtyping limits disease-wide enrollment.
She describes how 'exceptional responders' can be referred to the NCI for genotyping, and schemes to match patie…
Descargo de responsabilidad: El podcast y el arte incluidos en esta página son de ecancer.org, que es propiedad de su propietario y no está afiliado ni respaldado por Listen Notes, Inc.
EDITAR
Gracias por ayudar a mantener actualizada la base de datos de podcasts.
